News
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio ...
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing Vivani Medical, Inc. Wed, Mar 26, 2025, 7:30 AM 8 min read ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback